QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
NASDAQ:TCRT

Alaunos Therapeutics (TCRT) Stock Forecast, Price & News

$0.47
+0.01 (+2.15%)
(As of 06/6/2023 ET)
Compare
Today's Range
$0.47
▼
$0.50
50-Day Range
$0.47
▼
$0.66
52-Week Range
$0.45
▼
$4.01
Volume
428,821 shs
Average Volume
706,032 shs
Market Capitalization
$114.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

Alaunos Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
531.7% Upside
$3.00 Price Target
Short Interest
Bearish
11.02% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.16) to ($0.20) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.34 out of 5 stars

Medical Sector

934th out of 981 stocks

Pharmaceutical Preparations Industry

446th out of 464 stocks

See Top Rated MarketRank™ Stocks Here

TCRT stock logo

About Alaunos Therapeutics (NASDAQ:TCRT) Stock

Alaunos Therapeutics, Inc. is a biopharmaceutical company and clinical-stage oncology-focused cell therapy company, which engages in the development of adoptive TCR engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. Its pipeline includes Library TCR-T cell and mblL-15 TCR-T cell Therapy. The company was founded in 2003 and is headquartered in Houston, TX.

Receive TCRT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alaunos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TCRT Stock News Headlines

May 26, 2023 | msn.com
Alaunos slips 17% on Phase 1/2 data for cancer cell therapy
May 25, 2023 | finance.yahoo.com
Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual Meeting
June 6, 2023 | Behind the Markets (Ad)
How A.I. Could Make Most 21st Century Diseases EXTINCT
On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...
May 18, 2023 | americanbankingnews.com
Alaunos Therapeutics, Inc. Expected to Post Q1 2024 Earnings of ($0.04) Per Share (NASDAQ:TCRT)
May 17, 2023 | americanbankingnews.com
FY2023 EPS Estimates for Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Reduced by Analyst
May 17, 2023 | uk.news.yahoo.com
One Alaunos Therapeutics Insider Raised Stake By 117% In Previous Year
May 17, 2023 | americanbankingnews.com
HC Wainwright Upgrades Alaunos Therapeutics (NASDAQ:TCRT) to "Buy"
May 15, 2023 | seekingalpha.com
Alaunos Therapeutics upgraded to buy at Wainwright on multiple catalysts
June 6, 2023 | Behind the Markets (Ad)
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software"
The Washington Post Reports it's: "A revolution in warfare." The Sunday Times Reports it's: "a revolutionary power." Early investors can reap 5,633% gains as England, Germany, Japan and Australia rush to sign contracts. Get the name of the stock here >>>
May 13, 2023 | finance.yahoo.com
Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Q1 2023 Earnings Call Transcript
May 11, 2023 | marketwatch.com
8-K: Alaunos Therapeutics, Inc.
May 10, 2023 | finanznachrichten.de
Alaunos Therapeutics, Inc.: Alaunos Therapeutics Reports First Quarter 2023 Financial Results
May 10, 2023 | msn.com
Alaunos Therapeutics GAAP EPS of -$0.04 in-line
May 10, 2023 | msn.com
Recap: Alaunos Therapeutics Q1 Earnings
May 10, 2023 | finance.yahoo.com
Alaunos Therapeutics Reports First Quarter 2023 Financial Results
May 8, 2023 | americanbankingnews.com
Alaunos Therapeutics (TCRT) Scheduled to Post Quarterly Earnings on Wednesday
May 3, 2023 | finance.yahoo.com
Alaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023
April 26, 2023 | finance.yahoo.com
Alaunos Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
April 25, 2023 | finance.yahoo.com
The past five years for Alaunos Therapeutics (NASDAQ:TCRT) investors has not been profitable
April 2, 2023 | barrons.com
Alaunos Therapeutics Inc.
March 30, 2023 | finance.yahoo.com
Alaunos Therapeutics Appoints Dr. Robert J. Hofmeister to Board of Directors
March 30, 2023 | americanbankingnews.com
Alaunos Therapeutics' (TCRT) Overweight Rating Reiterated at Wells Fargo & Company
March 29, 2023 | finance.yahoo.com
Alaunos Therapeutics to Participate in Upcoming Investor Conferences in April
March 10, 2023 | finance.yahoo.com
When Will Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Turn A Profit?
March 9, 2023 | msn.com
Alaunos Therapeutics's Return On Capital Employed Overview
March 9, 2023 | finance.yahoo.com
Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Q4 2022 Earnings Call Transcript
March 6, 2023 | msn.com
Earnings Outlook For Alaunos Therapeutics
See More Headlines

TCRT Price History

TCRT Company Calendar

Last Earnings
5/10/2023
Today
6/06/2023
Next Earnings (Estimated)
8/21/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TCRT
CUSIP
N/A
CIK
1107421
Web
www.alaunos.com
Phone
(346) 355-4099
Fax
617-241-2855
Employees
41
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.00
High Stock Price Forecast
$3.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+531.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.17)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-37,730,000.00
Net Margins
N/A
Pretax Margin
-1,300.14%
Return on Equity
-108.27%
Return on Assets
-59.63%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.24
Quick Ratio
2.24

Sales & Book Value

Annual Sales
$2.92 million
Price / Sales
39.14
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.18 per share
Price / Book
2.64

Miscellaneous

Outstanding Shares
240,630,000
Free Float
225,756,000
Market Cap
$114.28 million
Optionable
Optionable
Beta
0.18

Key Executives

  • Kevin S. Boyle
    Chief Executive Officer & Director
  • Timothy M. Cunningham
    Chief Financial Officer
  • Drew Deniger
    Vice President-Research & Development
  • Raffaele Baffa
    Chief Medical Officer & Executive VP-R&D
  • Abhishek Srivastava
    Vice President-Technical Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













TCRT Stock - Frequently Asked Questions

Should I buy or sell Alaunos Therapeutics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alaunos Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TCRT shares.
View TCRT analyst ratings or view top-rated stocks.

What is Alaunos Therapeutics' stock price forecast for 2023?

2 brokerages have issued 12-month price targets for Alaunos Therapeutics' shares. Their TCRT share price forecasts range from $3.00 to $3.00. On average, they anticipate the company's share price to reach $3.00 in the next twelve months. This suggests a possible upside of 531.7% from the stock's current price.
View analysts price targets for TCRT or view top-rated stocks among Wall Street analysts.

How have TCRT shares performed in 2023?

Alaunos Therapeutics' stock was trading at $0.6491 at the start of the year. Since then, TCRT stock has decreased by 26.8% and is now trading at $0.4749.
View the best growth stocks for 2023 here.

When is Alaunos Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our TCRT earnings forecast.

How were Alaunos Therapeutics' earnings last quarter?

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) issued its quarterly earnings results on Wednesday, May, 10th. The company reported ($0.04) EPS for the quarter, meeting the consensus estimate of ($0.04). During the same quarter in the prior year, the company earned ($0.05) earnings per share.

What is Alaunos Therapeutics' stock symbol?

Alaunos Therapeutics trades on the NASDAQ under the ticker symbol "TCRT."

Who are Alaunos Therapeutics' major shareholders?

Alaunos Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (2.11%), Geode Capital Management LLC (0.89%), Two Sigma Advisers LP (0.63%), Renaissance Technologies LLC (0.42%), Two Sigma Investments LP (0.41%) and Magnolia Capital Advisors LLC (0.19%).
View institutional ownership trends.

How do I buy shares of Alaunos Therapeutics?

Shares of TCRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alaunos Therapeutics' stock price today?

One share of TCRT stock can currently be purchased for approximately $0.47.

How much money does Alaunos Therapeutics make?

Alaunos Therapeutics (NASDAQ:TCRT) has a market capitalization of $114.28 million and generates $2.92 million in revenue each year. The company earns $-37,730,000.00 in net income (profit) each year or ($0.17) on an earnings per share basis.

How can I contact Alaunos Therapeutics?

Alaunos Therapeutics' mailing address is ONE FIRST AVENUE PARRIS BUILDING 34, BOSTON MA, 02129. The official website for the company is www.alaunos.com. The company can be reached via phone at (346) 355-4099, via email at dconnolly@ziopharm.com, or via fax at 617-241-2855.

This page (NASDAQ:TCRT) was last updated on 6/6/2023 by MarketBeat.com Staff

My Account -